Miriplatin hydrate is primarily used in the treatment of hepatocellular carcinoma (HCC), a common type of liver cancer. It is administered through transarterial chemoembolization (TACE), a procedure where the drug is delivered directly into the blood vessels supplying the tumor. This targeted approach helps to maximize the drug's efficacy while minimizing systemic side effects. Miriplatin hydrate works by releasing platinum ions that interfere with DNA replication in cancer cells, leading to their destruction. Its lipophilic nature allows it to remain in the tumor for an extended period, enhancing its therapeutic effect. This makes it a valuable option for patients with unresectable HCC, offering a localized treatment strategy to control tumor growth and improve patient outcomes.